Abstract 4343009: Development and Validation of an Echocardiographic Nomogram for Identifying Cardiac Amyloidosis in Patients with Left Ventricular Hypertrophy

Backgraound: Echocardiography is the principal non-invasive imaging modality for screening cardiac amyloidosis. This study aimed to establish a cohort of CA-associated left ventricular hypertrophy (CA-LVH) within a hospital-based population and to develop an echocardiographic identification model for CA using readily available echocardiographic parameters. Methods: This retrospective nested cohort study involved the collection of clinical and echocardiographic data from three hospitals affiliated with the West China Medical Center, Sichuan University, between January 1, 2008, and December 31, 2023. Results: A total of 185 CA patients who underwent 309 echocardiography examinations with 1,213 echocardiographic data points from in-hospital non-CA-LVH cases matched for age, gender, and body surface area were included. Multivariable logistic regression analysis identified a history of hypertension [odds ratio (OR): 0.04, 95% confidence interval (CI): 0.021-0.073], left ventricular internal diameter in diastole (LVID) [OR: 0.927, 95%CI: 0.878-0.977], left ventricular ejection fraction (LVEF) [OR: 0.95, 95%CI: 0.908-0.993], AMYLI score [OR: 1.088, 95%CI: 1.024-1.161], asymmetric hypertrophy [OR: 3.729, 95%CI: 1.884-7.441], granular sparkling [OR: 3.111, 95%CI: 1.355-7.431], mild pericardial effusion [OR: 2.77, 95%CI: 1.563-4.937], mild aortic regurgitation [OR: 2.353, 95%CI: 1.278-4.361], mild mitral regurgitation [OR: 4.331, 95%CI: 2.347-8.141], and mild tricuspid regurgitation [OR: 3.837, 95%CI: 2.026-7.358] as independent predictive factors for CA in LVH patients. The constructed nomogram model demonstrated high accuracy (0.91-0.92), specificity (0.91-0.92), sensitivity (0.90-0.91), positive predictive value (0.73), negative predictive value (0.93-0.98), and Youden index (0.81-0.83). Conclusion: The developed nomogram displayed remarkable predictive accuracy, which has the potential to enhance CA screening via routine echocardiography and strategically guide subsequent diagnostic evaluations.